About this Journal Submit a Manuscript Table of Contents
International Journal of Endocrinology
Volume 2012 (2012), Article ID 625434, 20 pages
http://dx.doi.org/10.1155/2012/625434
Review Article

Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement Therapy

Division of Endocrinology, Department of Medicine, Harbor UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA 90509, USA

Received 5 October 2011; Revised 4 December 2011; Accepted 7 December 2011

Academic Editor: Ana Claudia Latronico

Copyright © 2012 Prasanth N. Surampudi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. J. Gooren, “Late-onset hypogonadism,” Frontiers of Hormone Research, vol. 37, pp. 62–73, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. Morales and J. L. Tenover, “Androgen deficiency in the aging male: when, who, and how to investigate and treat,” Urologic Clinics of North America, vol. 29, no. 4, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. G. V. Frajese, M. U. de Martino, E. Calcagni et al., “The epidemiology of partialandrogen deficiency in aging men (PADAM),” Journal of Endocrinological Investigation, vol. 28, no. 3, pp. 3–7, 2005. View at Scopus
  4. A. Morales, C. C. Schulman, J. Tostain, and F. C. W. Wu, “Testosterone Deficiency Syndrome (TDS) needs to be named appropriately—the importance of accurate terminology,” European Urology, vol. 50, no. 3, pp. 407–409, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. M. Matsumoto, “Andropause: clinical implications of the decline in serum testosterone levels with aging in men,” The Journals of Gerontology A, vol. 57, no. 2, pp. M76–M99, 2002. View at Scopus
  6. F. C. W. Wu, A. Tajar, S. R. Pye et al., “Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 7, pp. 2737–2745, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Gray, H. A. Feldman, J. B. McKinlay, and C. Longcope, “Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study,” The Journal of Clinical Endocrinology & Metabolism, vol. 73, no. 5, pp. 1016–1025, 1991. View at Scopus
  8. S. M. Harman, E. J. Metter, J. D. Tobin, J. Pearson, and M. R. Blackman, “Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 2, pp. 724–731, 2001.
  9. A. B. Araujo, G. R. Esche, V. Kupelian et al., “Prevalence of symptomatic androgen deficiency in men,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 11, pp. 4241–4247, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. F. C. W. Wu, A. Tajar, J. M. Beynon et al., “Identification of late-onset hypogonadism in middle-aged and elderly men,” The New England Journal of Medicine, vol. 363, no. 2, pp. 123–135, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. T. G. Travison, A.-H. Nguyen, V. Naganathan et al., “Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the Concord Health and Ageing in Men Project,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 8, pp. 2464–2474, 2011. View at Publisher · View at Google Scholar · View at PubMed
  12. A. B. Araujo, A. B. O'Donnell, D. J. Brambilla et al., “Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 12, pp. 5920–5926, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. M. Kaufman and A. Vermeulen, “Declining gonadal function in elderly men,” Bailliere's Clinical Endocrinology and Metabolism, vol. 11, no. 2, pp. 289–309, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Orwoll, L. C. Lambert, L. M. Marshall et al., “Testosterone and estradiol among older men,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 4, pp. 1336–1344, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. Y. S. Wong, D. C. C. Chan, A. Hong, and J. Woo, “Prevalence of and risk factors for androgen deficiency in middle-aged men in Hong Kong,” Metabolism, vol. 55, no. 11, pp. 1488–1494, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. Kelleher, A. J. Conway, and D. J. Handelsman, “Blood testosterone threshold for androgen deficiency symptoms,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 8, pp. 3813–3817, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. Kapoor, H. Aldred, S. Clark, K. S. Channer, and T. H. Jones, “Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity,” Diabetes Care, vol. 30, no. 4, pp. 911–917, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M. Zitzmann, S. Faber, and E. Nieschlag, “Association of specific symptoms and metabolic risks with serum testosterone in older men,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 11, pp. 4335–4343, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. E. Morley, F. E. Kaiser, H. M. Perry III et al., “Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men,” Metabolism, vol. 46, no. 4, pp. 410–413, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Wylie and N. Froggatt, “Late onset hypogonadism, sexuality and fertility,” Human Fertility, vol. 13, no. 3, pp. 126–133, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. W. Rosner, “Sex steroids and the free hormone hypothesis,” Cell, vol. 124, no. 3, pp. 455–456, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. A. M. Traish, F. Saad, and A. Guay, “The dark side of testosterone deficiency: II. type 2 diabetes and insulin resistance,” Journal of Andrology, vol. 30, no. 1, pp. 23–32, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. N. Goncharov, G. Katsya, A. Dobracheva et al., “Serum testosterone measurement in men: evaluation of modern immunoassay technologies,” Aging Male, vol. 8, no. 3-4, pp. 194–202, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. J. E. Morley, F. E. Kaiser, R. Sih, R. Hajjar, and H. M. Perry III, “Testosterone and frailty,” Clinics in Geriatric Medicine, vol. 13, no. 4, pp. 685–695, 1997. View at Scopus
  25. J. E. Morley, H. M. Perry III, R. T. Kevorkian, and P. Patrick, “Comparison of screening questionnaires for the diagnosis of hypogonadism,” Maturitas, vol. 53, no. 4, pp. 424–429, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. R. C. Rosen, A. B. Araujo, M. K. Connor et al., “The NERI Hypogonadism screener: psychometric validation in male patients and controls,” Clinical Endocrinology, vol. 74, no. 2, pp. 248–256, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. Bhasin, G. R. Cunningham, F. J. Hayes et al., “Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 6, pp. 2536–2559, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. Vermeulen, L. Verdonck, and J. M. Kaufman, “A critical evaluation of simple methods for the estimation of free testosterone in serum,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 10, pp. 3666–3672, 1999. View at Scopus
  29. A. Manni, W. M. Pardridge, and W. Cefalu, “Bioavailability of albumin-bound testosterone,” The Journal of Clinical Endocrinology & Metabolism, vol. 61, no. 4, pp. 705–710, 1985.
  30. J. A. Resko and K. B. Eik-nes, “Diurnal testosterone levels in peripheral plasma of human male subjects,” The Journal of Clinical Endocrinology & Metabolism, vol. 26, no. 5, pp. 573–576, 1966. View at Scopus
  31. S. J. Winters, D. E. Kelley, and B. Goodpaster, “The analog free testosterone assay: are the results in men clinically useful?” Clinical Chemistry, vol. 44, no. 10, pp. 2178–2182, 1998. View at Scopus
  32. S. Furuyama, D. M. Mayes, and C. A. Nugent, “A radioimmunoassay for plasma testosterone,” Steroids, vol. 16, pp. 415–428, 1970. View at Scopus
  33. J. C. Chen, E. M. Zorn, M. C. Hallberg, and R. G. Wieland, “Antibodies to testosterone-3-bovine serum albumin, applied to assay of serum 17-beta-ol androgens,” Clinical Chemistry, vol. 17, no. 7, pp. 581–584, 1971. View at Scopus
  34. M. L. Dufau, K. J. Catt, T. Tsuruhara, and D. Ryan, “Radioimmunoassay of plasma testosterone,” Clinica Chimica Acta, vol. 37, pp. 109–116, 1972. View at Scopus
  35. C. Wang, G. Youatt, S. O'Connor, A. Dulmanis, and B. Hudson, “A simple radioimmunoassay for plasma testosterone plus 5α dihydrotestosterone,” Journal of Steroid Biochemistry, vol. 5, no. 6, pp. 551–555, 1974.
  36. S. Bhasin, A. Zhang, A. Coviello et al., “The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders,” Steroids, vol. 73, no. 13, pp. 1311–1317, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. W. Rosner and H. Vesper, “Toward excellence in testosterone testing: a consensus statement,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 10, pp. 4542–4548, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. C. Wang, D. H. Catlin, L. M. Demers, B. Starcevic, and R. S. Swerdloff, “Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 2, pp. 534–543, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. N. A. Mazer, “A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations,” Steroids, vol. 74, no. 6, pp. 512–519, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. G. Sartorius, L. P. Ly, K. Sikaris, R. McLachlan, and D. J. Handelsman, “Original article predictive accuracy and sources of variability in calculated free testosterone estimates,” Annals of Clinical Biochemistry, vol. 46, no. 2, pp. 137–143, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. L. P. Ly, G. Sartorius, L. Hull et al., “Accuracy of calculated free testosterone formulae in men,” Clinical Endocrinology, vol. 73, no. 3, pp. 382–388, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. C. Wang, E. Nieschlag, R. Swerdloff et al., “Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations,” Journal of Andrology, vol. 30, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at PubMed
  43. C. Wang, E. Nieschlag, R. S. Swerdloff et al., “ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males,” Aging Male, vol. 12, no. 1, pp. 5–12, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. B. Lunenfeld and E. Nieschlag, “Testosterone therapy in the aging male,” Aging Male, vol. 10, no. 3, pp. 139–153, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. C. Wang, R. Swerdloff, M. Kipnes et al., “New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 8, pp. 3821–3829, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. L. J. Gooren, “Advances in testosterone replacement therapy,” Frontiers of Hormone Research, vol. 37, pp. 32–51, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. L. J. Gooren, “A ten-year safety study of the oral androgen testosterone undecanoate,” Journal of Andrology, vol. 15, no. 3, pp. 212–215, 1994. View at Scopus
  48. P. J. Snyder, “Clinical use of androgens,” Annual Review of Medicine, vol. 35, pp. 207–217, 1984. View at Scopus
  49. P. J. Snyder and D. A. Lawrence, “Treatment of male hypogonadism with testosterone enanthate,” The Journal of Clinical Endocrinology & Metabolism, vol. 51, no. 6, pp. 1335–1339, 1980. View at Scopus
  50. E. Nieschlag, H. M. Behre, P. Bouchard et al., “Testosterone replacement therapy: current trends and future directions,” Human Reproduction Update, vol. 10, no. 5, pp. 409–419, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. E. Nieschlag, H. M. Behre, and S. Nieschlag, Testosterone: Action, Deficiency, Substitution, Cambridge University Press, Cambridge, UK, 3rd edition, 2004.
  52. C. Wang, M. Harnett, A. S. Dobs, and R. S. Swerdloff, “Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial,” Journal of Andrology, vol. 31, no. 5, pp. 457–465, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. F. Saad, A. Kamischke, A. Yassin et al., “More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate,” Asian Journal of Andrology, vol. 9, no. 3, pp. 291–297, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. C. Wang, M. Harnett, A. S. Dobs, and R. S. Swerdloff, “Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial,” Journal of Andrology, vol. 31, no. 5, pp. 457–465, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. L. J. Gooren and M. C. M. Bunck, “Transdermal testosterone delivery: testosterone patch and gel,” World Journal of Urology, vol. 21, no. 5, pp. 316–319, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. S. Arver, A. S. Dobs, A. W. Meikle et al., “Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men,” Clinical Endocrinology, vol. 47, no. 6, pp. 727–737, 1997. View at Scopus
  57. A. S. Dobs, A. W. Meikle, S. Arver, S. W. Sanders, K. E. Caramelli, and N. A. Mazer, “Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 10, pp. 3469–3478, 1999. View at Scopus
  58. E. Pfeil and A. S. Dobs, “Current and future testosterone delivery systems for treatment of the hypogonadal male,” Expert Opinion on Drug Delivery, vol. 5, no. 4, pp. 471–481, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. U. Srinivas-Shankar and F. C. W. Wu, “Frailty and muscle function: role for testosterone?” Frontiers of Hormone Research, vol. 37, pp. 133–149, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. B. Breuer, S. Trungold, C. Martucci et al., “Relationships of sex hormone levels to dependence in activities of daily living in the frail elderly,” Maturitas, vol. 39, no. 2, pp. 147–159, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. R. N. Baumgartner, D. L. Waters, D. Gallagher, J. E. Morley, and P. J. Garry, “Predictors of skeletal muscle mass in elderly men and women,” Mechanisms of Ageing and Development, vol. 107, no. 2, pp. 123–136, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. D. A. Galvão, D. R. Taaffe, N. Spry, D. Joseph, D. Turner, and R. U. Newton, “Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation,” Prostate Cancer and Prostatic Diseases, vol. 12, no. 2, pp. 198–203, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. J. Svartberg, I. Agledahl, Y. Figenschau, T. Sildnes, K. Waterloo, and R. Jorde, “Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip,” International Journal of Impotence Research, vol. 20, no. 4, pp. 378–387, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. S. T. Page, J. K. Amory, F. D. Bowman et al., “Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 3, pp. 1502–1510, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. R. Sih, J. E. Morley, F. E. Kaiser, H. M. Perry III, P. Patrick, and C. Ross, “Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 6, pp. 1661–1667, 1997. View at Scopus
  66. H. M. Perry III, D. K. Miller, P. Patrick, and J. E. Morley, “Testosterone and leptin in older African-American men: relationship to age, strength, function, and season,” Metabolism, vol. 49, no. 8, pp. 1085–1091, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. U. Srinivas-Shankar, S. A. Roberts, M. J. Connolly et al., “Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 2, pp. 639–650, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. J. E. Clague, F. C. W. Wu, and M. A. Horan, “Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men,” International Journal of Andrology, vol. 22, no. 4, pp. 261–265, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. A. M. Isidori, E. Giannetta, E. A. Greco et al., “Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis,” Clinical Endocrinology, vol. 63, no. 3, pp. 280–293, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. K. S. Nair, R. A. Rizza, P. O'Brien et al., “DHEA in elderly women and DHEA or testosterone in elderly men,” The New England Journal of Medicine, vol. 355, no. 16, pp. 1647–1659, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. S. Bhasin, O. M. Calof, T. W. Storer et al., “Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging,” Nature Clinical Practice Endocrinology and Metabolism, vol. 2, no. 3, pp. 146–159, 2006. View at Publisher · View at Google Scholar · View at PubMed
  72. N. Garatachea, O. Molinero, R. Martínez-García, R. Jiménez-Jiménez, J. González-Gallego, and S. Márquez, “Feelings of well being in elderly people: relationship to physical activity and physical function,” Archives of Gerontology and Geriatrics, vol. 48, no. 3, pp. 306–312, 2009. View at Publisher · View at Google Scholar · View at PubMed
  73. J. E. Compston, “Sex steroids and bone,” Physiological Reviews, vol. 81, no. 1, pp. 419–447, 2001. View at Scopus
  74. A. W. van den Beld, F. H. de Jong, D. E. Grobbee, H. A. P. Pols, and S. W. J. Lamberts, “Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 9, pp. 3276–3282, 2000. View at Scopus
  75. H. Michael, P. L. Härkönen, H. K. Väänänen, and T. A. Hentunen, “Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption,” Journal of Bone and Mineral Research, vol. 20, no. 12, pp. 2224–2232, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. S. Khosla, L. J. Melton III, E. J. Atkinson, and W. M. O'Fallon, “Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 8, pp. 3555–3561, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Amin, Y. Zhang, C. T. Sawin et al., “Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study,” Annals of Internal Medicine, vol. 133, no. 12, pp. 951–963, 2000. View at Scopus
  78. J. M. Kaufman, “Role of sex steroids in the regulation of bone metabolism in the adult skeleton,” Annales d'Endocrinologie, vol. 67, no. 2, pp. 119–122, 2006. View at Scopus
  79. E. Wehr, S. Pilz, B. O. Boehm, W. März, and B. Obermayer-Pietsch, “Association of vitamin D status with serum androgen levels in men,” Clinical Endocrinology, vol. 73, no. 2, pp. 243–248, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. J. Meng, C. Ohlsson, G. A. Laughlin et al., “Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in men study,” Kidney International, vol. 78, no. 4, pp. 415–422, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. H. A. Fink, S. K. Ewing, K. E. Ensrud et al., “Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 10, pp. 3908–3915, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. H. Liu, N. M. Paige, C. L. Goldzweig et al., “Screening for osteoporosis in men: a systematic review for an american college of physicians guideline,” Annals of Internal Medicine, vol. 148, no. 9, pp. 685–701, 2008. View at Scopus
  83. C. Meier, T. V. Nguyen, D. J. Handelsman et al., “Endogenous sex hormones and incident fracture risk in older men: the Dubbo osteoporosis epidemiology study,” Archives of Internal Medicine, vol. 168, no. 1, pp. 47–54, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. M. R. Smith, “Treatment-related osteoporosis in men with prostate cancer,” Clinical Cancer Research, vol. 12, pp. 6315s–6319s, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. S. Amin, Y. Zhang, D. T. Felson et al., “Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study,” American Journal of Medicine, vol. 119, no. 5, pp. 426–433, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. H. M. Behre, S. Kliesch, E. Leifke, T. M. Link, and E. Nieschlag, “Long-term effect of testosterone therapy on bone mineral density in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 8, pp. 2386–2390, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Saggese, S. Bertelloni, and G. I. Baroncelli, “Sex steroids and the acquisition of bone mass,” Hormone Research, vol. 48, supplement 5, pp. 65–71, 1997. View at Scopus
  88. M. J. Tracz, K. Sideras, E. R. Boloña et al., “Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 6, pp. 2011–2016, 2006. View at Publisher · View at Google Scholar · View at PubMed
  89. Z. Merza, A. Blumsohn, P. M. Mah et al., “Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism,” International Journal of Andrology, vol. 29, no. 3, pp. 381–391, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. J. K. Amory, N. B. Watts, K. A. Easley et al., “Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 2, pp. 503–510, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. C. Wang, G. Cunningham, A. Dobs et al., “Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 5, pp. 2085–2098, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Basurto, A. Zarate, R. Gomez, C. Vargas, R. Saucedo, and R. Galván, “Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men,” Aging Male, vol. 11, no. 3, pp. 140–145, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. P. J. Snyder, H. Peachey, P. Hannoush et al., “Effect of testosterone treatment on bone mineral density in men over 65 years of age,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 6, pp. 1966–1972, 1999. View at Scopus
  94. J. S. Brand, I. van der Tweel, D. E. Grobbee, M. H. Emmelot-Vonk, and Y. T. van der Schouw, “Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies,” International Journal of Epidemiology, vol. 40, no. 1, Article ID dyq158, pp. 189–207, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. C. A. Allan and R. I. McLachlan, “Androgens and obesity,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 17, no. 3, pp. 224–232, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. P. Dandona, S. Dhindsa, A. Chaudhuri, V. Bhatia, S. Topiwala, and P. Mohanty, “Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome,” Current Molecular Medicine, vol. 8, no. 8, pp. 816–828, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Kapoor, C. J. Malkin, K. S. Channer, and T. H. Jones, “Androgens, insulin resistance and vascular disease in men,” Clinical Endocrinology, vol. 63, no. 3, pp. 239–250, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. P. Dandona, S. Dhindsa, A. Chaudhuri, V. Bhatia, and S. Topiwala, “Hypogonadotrophic hypogonadism in type 2 diabetes,” Aging Male, vol. 11, no. 3, pp. 107–117, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. P. Marin, S. Holmäng, C. Gustafsson et al., “Androgen treatment of abdominally obese men,” Obesity research, vol. 1, no. 4, pp. 245–251, 1993.
  100. T. H. Jones and F. Saad, “The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process,” Atherosclerosis, vol. 207, no. 2, pp. 318–327, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. O. M. Calof, A. B. Singh, M. L. Lee et al., “Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials,” The Journals of Gerontology A, vol. 60, no. 11, pp. 1451–1457, 2005. View at Scopus
  102. T. Münzer, S. M. Harman, P. Hees et al., “Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 8, pp. 3604–3610, 2001. View at Publisher · View at Google Scholar
  103. A. E. Heufelder, F. Saad, M. C. Bunck, and L. Gooren, “Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone,” Journal of Andrology, vol. 30, no. 6, pp. 726–733, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. S. Y. Kalinchenko, Y. A. Tishova, G. J. Mskhalaya, L. J. Gooren, E. J. Giltay, and F. Saad, “Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study,” Clinical Endocrinology, vol. 73, no. 5, pp. 602–612, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. T. H. Jones, S. Arver, H. M. Behre et al., “Testosterone replacement in hypogonadal men with Type 2 diabetes and/or metabolic syndrome (the TIMES2 study),” Diabetes Care, vol. 34, no. 4, pp. 828–837, 2011. View at Publisher · View at Google Scholar · View at PubMed
  106. D. Kapoor, S. Clarke, R. Stanworth, K. S. Channer, and T. H. Jones, “The effect of testosterone replacement theraphy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes,” European Journal of Endocrinology, vol. 156, no. 5, pp. 595–602, 2007. View at Publisher · View at Google Scholar · View at PubMed
  107. D. Kapoor, E. Goodwin, K. S. Channer, and T. H. Jones, “Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes,” European Journal of Endocrinology, vol. 154, no. 6, pp. 899–906, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. P. Marin, L. Lönn, B. Andersson et al., “Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 3, pp. 1018–1022, 1996. View at Publisher · View at Google Scholar
  109. E. A. Whitsel, E. J. Boyko, A. M. Matsumoto, B. D. Anawalt, and D. S. Siscovick, “Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis,” American Journal of Medicine, vol. 111, no. 4, pp. 261–269, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. M. M. Fernández-Balsells, M. H. Murad, M. Lane et al., “Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 6, pp. 2560–2575, 2010. View at Publisher · View at Google Scholar · View at PubMed
  111. S. T. Page, B. A. Mohr, C. L. Link, A. B. O'Donnell, W. J. Bremner, and J. B. Mckinlay, “Higher testosterone levels are associated with increased high-density lipoprotein cholesterol in men with cardiovascular disease: results from the Massachusetts Male Aging Study,” Asian Journal of Andrology, vol. 10, no. 2, pp. 193–200, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. S. K. Singh, R. Goyal, and D. D. Pratyush, “Is hypoandrogenemia a component of metabolic syndrome in males?” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 1, pp. 30–35, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. G. A. Wittert, I. M. Chapman, M. T. Haren, S. Mackintosh, P. Coates, and J. E. Morley, “Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status,” The Journals of Gerontology A, vol. 58, no. 7, pp. 618–625, 2003. View at Scopus
  114. S. Dhindsa, S. Prabhakar, M. Sethi, A. Bandyopadhyay, A. Chaudhuri, and P. Dandona, “Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 11, pp. 5462–5468, 2004. View at Publisher · View at Google Scholar · View at PubMed
  115. E. Selvin, M. Feinleib, L. Zhang et al., “Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III),” Diabetes Care, vol. 30, no. 2, pp. 234–238, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. P. Dandona and M. T. Rosenberg, “A practical guide to male hypogonadism in the primary care setting,” International Journal of Clinical Practice, vol. 64, no. 6, pp. 682–696, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. C. Wang, G. Jackson, T. H. Jones et al., “Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes,” Diabetes care, vol. 34, no. 7, pp. 1669–1675, 2011.
  118. G. Corona, M. Monami, G. Rastrelli et al., “Type 2 diabetes mellitus and testosterone: a meta-analysis study,” International Journal of Andrology, vol. 34, no. 6, pp. 528–540, 2011. View at Publisher · View at Google Scholar · View at PubMed
  119. L. A. Colangelo, P. Ouyang, K. Liu et al., “Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis,” Diabetes Care, vol. 32, no. 6, pp. 1049–1051, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  120. I. Agledahl, J.-B. Hansen, and J. Svartberg, “Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 68, no. 7, pp. 641–648, 2008. View at Publisher · View at Google Scholar
  121. M. A. Yialamas, A. A. Dwyer, E. Hanley, H. Lee, N. Pitteloud, and F. J. Hayes, “Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 11, pp. 4254–4259, 2007. View at Publisher · View at Google Scholar · View at PubMed
  122. A. Aversa, R. Bruzziches, D. Francomano et al., “Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study,” The Journal of Sexual Medicine, vol. 7, no. 10, pp. 3495–3503, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. R. D. Jones, J. E. Nettleship, D. Kapoor, H. T. Jones, and K. S. Channer, “Testosterone and atherosclerosis in aging men: purported association and clinical implications,” American Journal of Cardiovascular Drugs, vol. 5, no. 3, pp. 141–154, 2005. View at Scopus
  124. G. Kabakci, A. Yildirir, I. Can, I. Unsal, and B. Erbas, “Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography,” Cardiology, vol. 92, no. 4, pp. 221–225, 1999. View at Scopus
  125. R. Shabsigh, M. Katz, G. Yan, and N. Makhsida, “Cardiovascular issues in hypogonadism and testosterone therapy,” American Journal of Cardiology, vol. 96, pp. 67M–72M, 2005.
  126. J. E. Nettleship, R. D. Jones, K. S. Channer, and T. H. Jones, “Testosterone and coronary artery disease,” Frontiers of Hormone Research, vol. 37, pp. 91–107, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. M. Muller, A. W. van den Beld, M. L. Bots, D. E. Grobbee, S. W. J. Lamberts, and Y. T. van der Schouw, “Endogenous sex hormones and progression of carotid atherosclerosis in elderly men,” Circulation, vol. 109, no. 17, pp. 2074–2079, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. Å. Tivesten, D. Mellström, H. Jutberger et al., “Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden,” Journal of the American College of Cardiology, vol. 50, no. 11, pp. 1070–1076, 2007. View at Publisher · View at Google Scholar · View at PubMed
  129. A. E. Hak, J. C.M. Witteman, F. H. de Jong, M. I. Geerlings, A. Hofman, and H. A. P. Pols, “Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 8, pp. 3632–3639, 2002. View at Publisher · View at Google Scholar
  130. M. M. Shores, A. M. Matsumoto, K. L. Sloan, and D. R. Kivlahan, “Low serum testosterone and mortality in male veterans,” Archives of Internal Medicine, vol. 166, no. 15, pp. 1660–1665, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. G. A. Laughlin, E. Barrett-Connor, and J. Bergstrom, “Low serum testosterone and mortality in older men,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 1, pp. 68–75, 2008. View at Publisher · View at Google Scholar · View at PubMed
  132. R. Haring, H. Völzke, A. Steveling et al., “Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79,” European Heart Journal, vol. 31, no. 12, pp. 1494–1501, 2010. View at Publisher · View at Google Scholar · View at PubMed
  133. C. J. Malkin, P. J. Pugh, P. D. Morris, S. Asif, T. H. Jones, and K. S. Channer, “Low serum testosterone and increased mortality in men with coronary heart disease,” Heart, vol. 96, no. 22, pp. 1821–1825, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. M. Maggio, F. Lauretani, G. P. Ceda et al., “Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the chianti area (InCHIANTI) study,” Archives of Internal Medicine, vol. 167, no. 20, pp. 2249–2254, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. K. T. Khaw, M. Dowsett, E. Folkerd et al., “Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: european prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study,” Circulation, vol. 116, no. 23, pp. 2694–2701, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. A. B. Araujo, J. M. Dixon, E. A. Suarez, M. H. Murad, L. T. Guey, and G. A. Wittert, “Endogenous testosterone and mortality in men: A systematic review and meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 10, pp. 3007–3019, 2011. View at Publisher · View at Google Scholar · View at PubMed
  137. P. J. Snyder, “Might testosterone actually reduce mortality?” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 1, pp. 32–33, 2008. View at Publisher · View at Google Scholar · View at PubMed
  138. K. M. English, R. P. Steeds, T. H. Jones, M. J. Diver, and K. S. Channer, “Low-dose transdermal testosterone therapy improves angina threshold in men with chromic stable angina: a randomized, double-blind, placebo-controlled study,” Circulation, vol. 102, no. 16, pp. 1906–1911, 2000. View at Scopus
  139. C. J. Malkin, P. J. Pugh, P. D. Morris et al., “Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life,” Heart, vol. 90, no. 8, pp. 871–876, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. T. H. Jones, “Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome,” Journal of Diabetes, vol. 2, no. 3, pp. 146–156, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  141. G. Caminiti, M. Volterrani, F. Iellamo et al., “Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study,” Journal of the American College of Cardiology, vol. 54, no. 10, pp. 919–927, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  142. R. M. Haddad, C. C. Kennedy, S. M. Caples et al., “Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials,” Mayo Clinic Proceedings, vol. 82, no. 1, pp. 29–39, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  143. C. A. Allan and R. I. McLachlan, “Age-related changes in testosterone and the role of replacement therapy in older men,” Clinical Endocrinology, vol. 60, no. 6, pp. 653–670, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  144. R. R. Hajjar, F. E. Kaiser, and J. E. Morley, “Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 11, pp. 3793–3796, 1997.
  145. C. M. Meston, “Aging and sexuality,” Western Journal of Medicine, vol. 167, no. 4, pp. 285–290, 1997. View at Scopus
  146. W. Krause, U. Mueller, and A. Mazur, “Testosterone supplementation in the aging male: which questions have been answered?” Aging Male, vol. 8, no. 1, pp. 31–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. R. Shabsigh, J. Rajfer, A. Aversa et al., “The evolving role of testosterone in the treatment of erectile dysfunction,” International Journal of Clinical Practice, vol. 60, no. 9, pp. 1087–1092, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  148. A. A. Yassin and F. Saad, “Improvement of sexual function in Men with late-onset hypogonadism treated with testosterone only,” The Journal of Sexual Medicine, vol. 4, no. 2, pp. 497–501, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  149. A. A. Yassin and F. Saad, “Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature,” Andrologia, vol. 38, no. 1, pp. 34–37, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  150. P. Jain, A. W. Rademaker, and K. T. Mcvary, “Testosterone supplementation for erectile dysfunction: results of a meta-analysis,” The Journal of Urology, vol. 164, no. 2, pp. 371–375, 2000. View at Scopus
  151. E. R. Boloña, M. V. Uraga, R. M. Haddad et al., “Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials,” Mayo Clinic Proceedings, vol. 82, no. 1, pp. 20–28, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  152. A. M. Isidori, E. Giannetta, D. Gianfrilli et al., “Effects of testosterone on sexual function in men: results of a meta-analysis,” Clinical Endocrinology, vol. 63, no. 4, pp. 381–394, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  153. M. M. Shores, V. M. Moceri, K. L. Sloan, A. M. Matsumoto, and D. R. Kivlahan, “Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity,” Journal of Clinical Psychiatry, vol. 66, no. 1, pp. 7–14, 2005. View at Scopus
  154. S. N. Seidman, E. Spatz, C. Rizzo, and S. P. Roose, “Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial,” Journal of Clinical Psychiatry, vol. 62, no. 6, pp. 406–412, 2001. View at Scopus
  155. C. Wang, G. Alexander, N. Berman et al., “Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 10, pp. 3578–3583, 1996. View at Publisher · View at Google Scholar
  156. J. E. Morley, “Testosterone replacement in older men and women,” Journal of Gender-Specific Medicine, vol. 4, no. 2, pp. 49–53, 2001. View at Scopus
  157. C. Wang, R. S. Swerdloff, A. Iranmanesh et al., “Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 8, pp. 2839–2853, 2000. View at Publisher · View at Google Scholar
  158. C. A. Orengo, L. Fullerton, and M. E. Kunik, “Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy,” Journal of Geriatric Psychiatry and Neurology, vol. 18, no. 1, pp. 20–24, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  159. F. A. Zarrouf, S. Artz, J. Griffith, C. Sirbu, and M. Kommor, “Testosterone and depression: systematic review and meta-analysis,” Journal of Psychiatric Practice, vol. 15, no. 4, pp. 289–305, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  160. R. Amiaz and S. N. Seidman, “Testosterone and depression in men,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 15, no. 3, pp. 278–283, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  161. N. T. Shamlian and M. G. Cole, “Androgen treatment of depressive symptoms in older men: a systematic review of feasibility and effectiveness,” Canadian Journal of Psychiatry, vol. 51, no. 5, pp. 295–299, 2006. View at Scopus
  162. S. D. Moffat, A. B. Zonderman, E. Jeffrey Metter, M. R. Blackman, S. Mitchell Harman, and S. M. Resnick, “Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 11, pp. 5001–5007, 2002. View at Publisher · View at Google Scholar
  163. P. P. Thilers, S. W. S. MacDonald, and A. Herlitz, “The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-oldmen and women,” Psychoneuroendocrinology, vol. 31, no. 5, pp. 565–576, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  164. M. Muller, A. Aleman, D. E. Grobbee, E. H. F. de Haan, and Y. T. van der Schouw, “Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level?” Neurology, vol. 64, no. 5, pp. 866–871, 2005. View at Scopus
  165. J. S. Janowsky, B. Chavez, and E. Orwoll, “Sex steroids modify working memory,” Journal of Cognitive Neuroscience, vol. 12, no. 3, pp. 407–414, 2000. View at Scopus
  166. J. S. Janowsky, S. K. Oviatt, and E. S. Orwoll, “Testosterone influences spatial cognition in older men,” Behavioral Neuroscience, vol. 108, no. 2, pp. 325–332, 1994. View at Publisher · View at Google Scholar · View at Scopus
  167. E. Hogervorst, S. Bandelow, M. Combrinck, and A. D. Smith, “Low free testosterone is an independent risk factor for Alzheimer's disease,” Experimental Gerontology, vol. 39, no. 11-12, pp. 1633–1639, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  168. O. Beauchet, “Testosterone and cognitive function: current clinical evidence of a relationship,” European Journal of Endocrinology, vol. 155, no. 6, pp. 773–781, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  169. R. S. Tan and S. J. Pu, “A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease,” Aging Male, vol. 6, no. 1, pp. 13–17, 2003. View at Scopus
  170. M. M. Cherrier, S. Craft, and A. H. Matsumoto, “Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report,” Journal of Andrology, vol. 24, no. 4, pp. 568–576, 2003. View at Scopus
  171. M. M. Cherrier, A. M. Matsumoto, J. K. Amory et al., “Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment,” Neurology, vol. 64, no. 12, pp. 2063–2068, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  172. A. M. Kenny, S. Bellantonio, C. A. Gruman, R. D. Acosta, and K. M. Prestwood, “Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels,” The Journals of Gerontology A, vol. 57, no. 5, pp. M321–M325, 2002. View at Scopus
  173. A. M. Kenny, G. Fabregas, C. Song, B. Biskup, and S. Bellantonio, “Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss,” The Journals of Gerontology A, vol. 59, no. 1, pp. 75–78, 2004. View at Scopus
  174. M. H. Emmelot-Vonk, H. J. J. Verhaar, H. R. Nakhai Pour et al., “Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial,” The Journal of the American Medical Association, vol. 299, no. 1, pp. 39–52, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  175. J. E. Yonker, E. Eriksson, L. G. Nilsson, and A. Herlitz, “Negative association of testosterone on spatial visualization in 35 to 80 year old men,” Cortex, vol. 42, no. 3, pp. 376–386, 2006. View at Publisher · View at Google Scholar · View at Scopus
  176. E. J. Chahla, M. E. Hayek, and J. E. Morley, “Testosterone replacement therapy and cardiovascular risk factors modification,” Aging Male, vol. 14, no. 2, pp. 83–90, 2011. View at Publisher · View at Google Scholar · View at PubMed
  177. A. Mathur, C. Malkin, B. Saeed, R. Muthusamy, T. Hugh Jones, and K. Channer, “Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men,” European Journal of Endocrinology, vol. 161, no. 3, pp. 443–449, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  178. C. J. Malkin, K. S. Channer, and T. H. Jones, “Testosterone and heart failure,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 17, no. 3, pp. 262–268, 2010. View at Publisher · View at Google Scholar · View at PubMed
  179. U. H. Nam, M. Wang, P. R. Crisostomo et al., “The effect of chronic exogenous androgen on myocardial function following acute ischemia-reperfusion in hosts with different baseline levels of sex steroids,” Journal of Surgical Research, vol. 142, no. 1, pp. 113–118, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  180. S. Basaria, A. D. Coviello, T. G. Travison et al., “Adverse events associated with testosterone administration,” The New England Journal of Medicine, vol. 363, no. 2, pp. 109–122, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  181. F. Lopez-Jimenez, F. H. Sert Kuniyoshi, A. Gami, and V. K. Somers, “Obstructive sleep apnea: implications for cardiac and vascular disease,” Chest, vol. 133, no. 3, pp. 793–804, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  182. V. K. Kapur, “Obstructive sleep apnea: diagnosis, epidemiology, and economics,” Respiratory Care, vol. 55, no. 9, pp. 1155–1167, 2010. View at Scopus
  183. A. G. P. de Sousa, C. Cercato, M. C. Mancini, and A. Halpern, “Obesity and obstructive sleep apnea-hypopnea syndrome,” Obesity Reviews, vol. 9, no. 4, pp. 340–354, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  184. N. P. Goncharov, G. V. Katsya, N. A. Chagina, and L. J. Gooren, “Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone,” Aging Male, vol. 11, no. 3, pp. 118–122, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  185. R. Shabsigh, S. Arver, K. S. Channer et al., “The triad of erectile dysfunction, hypogonadism and the metabolic syndrome,” International Journal of Clinical Practice, vol. 62, no. 5, pp. 791–798, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  186. A. Hoekema, A. L. Stel, B. Stegenga et al., “Sexual function and obstructive sleep apnea-hypopnea: a randomized clinical trial evaluating the effects of oral-appliance and continuous positive airway pressure therapy,” The Journal of Sexual Medicine, vol. 4, no. 4, pp. 1153–1162, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  187. M. L. Andersen and S. Tufik, “The effects of testosterone on sleep and sleep-disordered breathing in men: its bidirectional interaction with erectile function,” Sleep Medicine Reviews, vol. 12, no. 5, pp. 365–379, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  188. E. Barrett-Connor, T.-T. Dam, K. Stone, S. L. Harrison, S. Redline, and E. Orwoll, “The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 7, pp. 2602–2609, 2008. View at Publisher · View at Google Scholar · View at PubMed
  189. A. M. Matsumoto, R. E. Sandblom, and R. B. Schoene, “Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep,” Clinical Endocrinology, vol. 22, no. 6, pp. 713–721, 1985.
  190. B. K. Schneider, C. K. Pickett, and C. W. Zwillich, “Influence of testosterone on breathing during sleep,” Journal of Applied Physiology, vol. 61, no. 2, pp. 618–623, 1986.
  191. H. M. Hanafy, “Testosterone therapy and obstructive sleep apnea: is there a real connection?” The Journal of Sexual Medicine, vol. 4, no. 5, pp. 1241–1246, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  192. S. Ismailogullari, C. Korkmaz, Y. Peker, F. Bayram, Z. Karaca, and M. Aksu, “Impact of long-term gonadotropin replacement treatment on sleep in men with idiopathic hypogonadotropic hypogonadism,” The Journal of Sexual Medicine, vol. 8, no. 7, pp. 2090–2097, 2011. View at Publisher · View at Google Scholar · View at PubMed
  193. S. W. Kim, J. H. Hwang, J. M. Cheon et al., “Direct and indirect effects of androgens on survival of hematopoietic progenitor cells in vitro,” Journal of Korean Medical Science, vol. 20, no. 3, pp. 409–416, 2005. View at Scopus
  194. S. Basaria and A. S. Dobs, “Risks versus benefits of testosterone therapy in elderly men,” Drugs and Aging, vol. 15, no. 2, pp. 131–142, 1999. View at Publisher · View at Google Scholar · View at Scopus
  195. V. A. Kozlov, I. G. Tsyrlova, and I. N. Zhuravkin, “Differences in the effect of testosterone on multipotent stem hemopoietic cells and immunocompetent B lymphocytes,” Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, vol. 56, no. 9, pp. 72–76, 1979.
  196. Y. G. Cui, J. S. Tong, Q. Q. Pan et al., “Effect of androgen on erythropoietin in patients with hypogonadism,” Zhonghua nan ke xue, vol. 9, no. 4, pp. 248–251, 2003. View at Scopus
  197. F. F. Ip, I. di Pierro, R. Brown, I. Cunningham, D. J. Handelsman, and P. Y. Liu, “Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets,” European Journal of Endocrinology, vol. 162, no. 2, pp. 385–390, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  198. A. D. Coviello, B. Kaplan, K. M. Lakshman, T. Chen, A. B. Singh, and S. Bhasin, “Effects of graded doses of testosterone on erythropoiesis in healthy young and older men,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 3, pp. 914–919, 2008. View at Publisher · View at Google Scholar · View at PubMed
  199. M. Zitzmann and E. Nieschlag, “Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 10, pp. 3844–3853, 2007. View at Publisher · View at Google Scholar · View at PubMed
  200. Y. C. Kim, “Testosterone supplementation in the aging male,” International Journal of Impotence Research, vol. 11, no. 6, pp. 343–352, 1999. View at Scopus
  201. J. F. Viallard, G. Marit, P. Mercié, B. Leng, J. Reiffers, and J. L. Pellegrin, “Polycythaemia as a complication of transdermal testosterone therapy,” British Journal of Haematology, vol. 110, no. 1, pp. 237–238, 2000. View at Publisher · View at Google Scholar
  202. N. Bassil, S. Alkaade, and J. E. Morley, “The benefits and risks of testosterone replacement therapy: a review,” Therapeutics and Clinical Risk Management, vol. 5, no. 1, pp. 427–448, 2009. View at Scopus
  203. L. E. Allport, M. W. Parsons, K. S. Butcher et al., “Elevated hematocrit is associated with reduced reperfusion and tissue survival in acute stroke,” Neurology, vol. 65, no. 9, pp. 1382–1387, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  204. H. C. Kwaan and J. Wang, “Hyperviscosity in polycythemia vera and other red cell abnormalities,” Seminars in Thrombosis and Hemostasis, vol. 29, no. 5, pp. 451–458, 2003. View at Publisher · View at Google Scholar · View at PubMed
  205. B. I. Lee, H. S. Nam, J. H. Heo et al., “Yonsei Stroke Registry: analysis of 1,000 patients with acute cerebral infarctions,” Cerebrovascular Diseases, vol. 12, no. 3, pp. 145–151, 2001. View at Publisher · View at Google Scholar · View at Scopus
  206. D. W. Brown, W. H. Giles, and J. B. Croft, “Hematocrit and the risk of coronary heart disease mortality,” American Heart Journal, vol. 142, no. 4, pp. 657–663, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  207. G. Greenberg, A. Assali, H. Vaknin-Assa et al., “Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction,” American Journal of Cardiology, vol. 105, no. 4, pp. 435–440, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  208. W. C. Wu, T. L. Schifftner, W. G. Henderson et al., “Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery,” The Journal of the American Medical Association, vol. 297, no. 22, pp. 2481–2488, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  209. S. M. Petak, H. R. Nankin, R. F. Spark, R. S. Swerdloff, and L. J. Rodriguez-Rigau, “American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update,” Endocrine Practice, vol. 8, pp. 440–456, 2002.
  210. M. J. Curran and W. Bihrle III, “Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate,” Urology, vol. 53, no. 2, pp. 423–424, 1999. View at Publisher · View at Google Scholar · View at Scopus
  211. E. L. Rhoden and A. Morgentaler, “Risks of testosterone-replacement therapy and recommendations for monitoring,” The New England Journal of Medicine, vol. 350, no. 5, pp. 482–492, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  212. S. Sengupta, H. J. Duncan, R. J. Macgregor, and J. M. Russell, “The development of prostate cancer despite late onset androgen deficiency,” International Journal of Urology, vol. 12, no. 9, pp. 847–848, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  213. A. A. Yassin and F. Saad, “Testosterone and erectile dysfunction,” Journal of Andrology, vol. 29, no. 6, pp. 593–604, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  214. R. M. Coward, J. Simhan, and C. C. Carson, “Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy,” BJU International, vol. 103, no. 9, pp. 1179–1183, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  215. A. Morgentaler, “Testosterone replacement therapy and prostate cancer,” Urologic Clinics of North America, vol. 34, no. 4, pp. 555–563, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  216. J. M. Kaufman and R. J. Graydon, “Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men,” The Journal of Urology, vol. 172, no. 3, pp. 920–922, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  217. P. K. Agarwal and M. G. Oefelein, “Testosterone replacement therapy after primary treatment for prostate cancer,” The Journal of Urology, vol. 173, no. 2, pp. 533–536, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  218. M. F. Sarosdy, “Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy,” Cancer, vol. 109, no. 3, pp. 536–541, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  219. N. Mauras, V. Hayes, S. Welch et al., “Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity,” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 6, pp. 1886–1892, 1998. View at Publisher · View at Google Scholar
  220. U. Gruntmanis and G. D. Braunstein, “Treatment of gynecomastia,” Current Opinion in Investigational Drugs, vol. 2, no. 5, pp. 643–649, 2001. View at Scopus
  221. I. Kurokawa, F. W. Danby, Q. Ju et al., “New developments in our understanding of acne pathogenesis and treatment,” Experimental Dermatology, vol. 18, no. 10, pp. 821–832, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  222. D. Deplewski and R. L. Rosenfield, “Role of hormones in pilosebaceous unit development,” Endocrine Reviews, vol. 21, no. 4, pp. 363–392, 2000. View at Publisher · View at Google Scholar · View at Scopus
  223. L. J. Woodhouse, S. Reisz-Porszasz, M. Javanbakht et al., “Development of models to predict anabolic response to testosterone administration in healthy young men,” American Journal of Physiology, vol. 284, no. 5 47-5, pp. E1009–E1017, 2003.
  224. A. Haider, L. J. Gooren, P. Padungtod, and F. Saad, “Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men,” Andrologia, vol. 41, no. 1, pp. 7–13, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  225. S. Bhasin, L. Woodhouse, R. Casaburi et al., “Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 2, pp. 678–688, 2005. View at Publisher · View at Google Scholar · View at PubMed